Cargando…

5q Deletion Myelodysplastic Syndrome in a Young Male Patient

Myelodysplastic syndromes (MDS) are a diverse group of hematopoietic stem cell malignancies with various phenotypic variability that are categorized by abnormal differentiation of one or multiple cell lines of the bone marrow. A large part of the phenotypic heterogeneity is in part due to the wide s...

Descripción completa

Detalles Bibliográficos
Autores principales: Elkattawy, Sherif, Ayad, Sarah, El-Feki, Iman, Guo, Xutong, Appiah-Kubi, Edmund, Talpur, Afrah, Kessler, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464316/
https://www.ncbi.nlm.nih.gov/pubmed/34589360
http://dx.doi.org/10.7759/cureus.17466
_version_ 1784572607585058816
author Elkattawy, Sherif
Ayad, Sarah
El-Feki, Iman
Guo, Xutong
Appiah-Kubi, Edmund
Talpur, Afrah
Kessler, William
author_facet Elkattawy, Sherif
Ayad, Sarah
El-Feki, Iman
Guo, Xutong
Appiah-Kubi, Edmund
Talpur, Afrah
Kessler, William
author_sort Elkattawy, Sherif
collection PubMed
description Myelodysplastic syndromes (MDS) are a diverse group of hematopoietic stem cell malignancies with various phenotypic variability that are categorized by abnormal differentiation of one or multiple cell lines of the bone marrow. A large part of the phenotypic heterogeneity is in part due to the wide set of genetic defects related to MDS. Though clinically, MDS is centered on diagnostic measures that do not incorporate molecular genetic data, an isolated deletion of the long arm of chromosome 5 (del(5q)) is the only subset of MDS to be identified by genetic defects. This distinctive phenotype is termed 5q-syndrome. We report a case of a 25-year-old with a past medical history of polydactyly, severe anemia, and thrombocytopenia who presented to the emergency department with a chief complaint of weakness and fatigue. Bone marrow biopsy showed myeloid neoplasm with complex genetic abnormalities, nearly 100% hyperplastic marrow with marked trilineage dysplasia, relative myeloid hyperplasia with increased abnormal eosinophilic precursors, erythroid left shift, and atypical megakaryocytes. Fluorescence in situ hybridization (FISH) panel showed deletion of 5q-. Herein, we address the clinical course and morphological characteristics as well as possible therapeutic options for 5q syndrome.
format Online
Article
Text
id pubmed-8464316
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-84643162021-09-28 5q Deletion Myelodysplastic Syndrome in a Young Male Patient Elkattawy, Sherif Ayad, Sarah El-Feki, Iman Guo, Xutong Appiah-Kubi, Edmund Talpur, Afrah Kessler, William Cureus Oncology Myelodysplastic syndromes (MDS) are a diverse group of hematopoietic stem cell malignancies with various phenotypic variability that are categorized by abnormal differentiation of one or multiple cell lines of the bone marrow. A large part of the phenotypic heterogeneity is in part due to the wide set of genetic defects related to MDS. Though clinically, MDS is centered on diagnostic measures that do not incorporate molecular genetic data, an isolated deletion of the long arm of chromosome 5 (del(5q)) is the only subset of MDS to be identified by genetic defects. This distinctive phenotype is termed 5q-syndrome. We report a case of a 25-year-old with a past medical history of polydactyly, severe anemia, and thrombocytopenia who presented to the emergency department with a chief complaint of weakness and fatigue. Bone marrow biopsy showed myeloid neoplasm with complex genetic abnormalities, nearly 100% hyperplastic marrow with marked trilineage dysplasia, relative myeloid hyperplasia with increased abnormal eosinophilic precursors, erythroid left shift, and atypical megakaryocytes. Fluorescence in situ hybridization (FISH) panel showed deletion of 5q-. Herein, we address the clinical course and morphological characteristics as well as possible therapeutic options for 5q syndrome. Cureus 2021-08-26 /pmc/articles/PMC8464316/ /pubmed/34589360 http://dx.doi.org/10.7759/cureus.17466 Text en Copyright © 2021, Elkattawy et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Oncology
Elkattawy, Sherif
Ayad, Sarah
El-Feki, Iman
Guo, Xutong
Appiah-Kubi, Edmund
Talpur, Afrah
Kessler, William
5q Deletion Myelodysplastic Syndrome in a Young Male Patient
title 5q Deletion Myelodysplastic Syndrome in a Young Male Patient
title_full 5q Deletion Myelodysplastic Syndrome in a Young Male Patient
title_fullStr 5q Deletion Myelodysplastic Syndrome in a Young Male Patient
title_full_unstemmed 5q Deletion Myelodysplastic Syndrome in a Young Male Patient
title_short 5q Deletion Myelodysplastic Syndrome in a Young Male Patient
title_sort 5q deletion myelodysplastic syndrome in a young male patient
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464316/
https://www.ncbi.nlm.nih.gov/pubmed/34589360
http://dx.doi.org/10.7759/cureus.17466
work_keys_str_mv AT elkattawysherif 5qdeletionmyelodysplasticsyndromeinayoungmalepatient
AT ayadsarah 5qdeletionmyelodysplasticsyndromeinayoungmalepatient
AT elfekiiman 5qdeletionmyelodysplasticsyndromeinayoungmalepatient
AT guoxutong 5qdeletionmyelodysplasticsyndromeinayoungmalepatient
AT appiahkubiedmund 5qdeletionmyelodysplasticsyndromeinayoungmalepatient
AT talpurafrah 5qdeletionmyelodysplasticsyndromeinayoungmalepatient
AT kesslerwilliam 5qdeletionmyelodysplasticsyndromeinayoungmalepatient